{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:07:35Z","timestamp":1779246455312,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119230","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:24:11Z","timestamp":1774560251000},"page":"119230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The trophoblastic theory of cancer: Progesterone-dependent immune tolerance and modulation by synthetic and natural antagonists"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2712-9747","authenticated-orcid":false,"given":"Ba X.","family":"Hoang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh X.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuong","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1458-4265","authenticated-orcid":false,"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003052","article-title":"The end of the genetic paradigm of cancer","volume":"23","author":"Huang","year":"2025","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7203","key":"10.1016\/j.biopha.2026.119230_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"6024","key":"10.1016\/j.biopha.2026.119230_bib4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"9-10","key":"10.1016\/j.biopha.2026.119230_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.placenta.2005.12.006","article-title":"The uterine spiral arteries in human pregnancy: facts and controversies","volume":"27","author":"Pijnenborg","year":"2006","journal-title":"Placenta"},{"issue":"19","key":"10.1016\/j.biopha.2026.119230_bib6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJMra000763","article-title":"Implantation and the survival of early pregnancy","volume":"345","author":"Norwitz","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119230_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119230_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1387\/ijdb.082798ni","article-title":"Placental metabolic reprogramming: do changes in the mix of energy-generating substrates modulate fetal growth?","volume":"54","author":"Illsley","year":"2010","journal-title":"Int. J. Dev. Biol."},{"issue":"5-6","key":"10.1016\/j.biopha.2026.119230_bib9","first-page":"310","article-title":"The trophoblast theory of cancer (John Beard, 1857\u20131924) revisited","volume":"31","author":"Gurchot","year":"1975","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1534735408326454","article-title":"Of germ cells, trophoblasts, and cancer stem cells","volume":"7","author":"Burleigh","year":"2008","journal-title":"Integr. Cancer Ther."},{"issue":"6859","key":"10.1016\/j.biopha.2026.119230_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2026.119230_bib12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/mi.2017.35","article-title":"Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites","volume":"10","author":"Hall","year":"2017","journal-title":"Mucosal Immunol."},{"issue":"7560","key":"10.1016\/j.biopha.2026.119230_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2026.119230_bib16","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1210\/jc.2008-0938","article-title":"Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis","volume":"93","author":"Horwitz","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/humrep\/del126","article-title":"Progesterone regulates HLA-G gene expression through a novel progesterone response element","volume":"21","author":"Yie","year":"2006","journal-title":"Hum. Reprod."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1034\/j.1600-0897.2002.01133.x","article-title":"Progesterone induced blocking factor (PIBF) mediates progesterone induced suppression of decidual lymphocyte cytotoxicity","volume":"48","author":"La\u0161karin","year":"2002","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.biopha.2026.119230_bib19","first-page":"291","article-title":"The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene","volume":"54","author":"Giangrande","year":"1999","journal-title":"Recent Prog. Horm. Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119230_bib20","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1074\/jbc.M110090200","article-title":"Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells","volume":"277","author":"Richer","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pharmthera.2008.09.006","article-title":"PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding","volume":"121","author":"Rohe","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib22","first-page":"4862","article-title":"Beyond the increasing complexity of the immunomodulatory HLA-G molecule","volume":"111","author":"Carosella","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119230_bib23","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1158\/0008-5472.CAN-05-0097","article-title":"HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?","volume":"65","author":"Rouas-Freiss","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/ijms23031333","article-title":"Progesterone: a unique hormone with immunomodulatory roles in pregnancy","volume":"23","author":"Raghupathy","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119230_bib25","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3390\/biom12091299","article-title":"Progesterone as an anti-inflammatory drug and immunomodulator: new aspects in hormonal regulation of the inflammation","volume":"12","author":"Fedotcheva","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119230_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3389\/fimmu.2020.01685","article-title":"HLA-G neo-expression on tumors","volume":"11","author":"Loustau","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12967-024-04938-w","article-title":"Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119230_bib28","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.3390\/ijms21124528","article-title":"HLA-G: a new immune checkpoint in cancer?","volume":"21","author":"Krijgsman","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib29","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/ijms23062925","article-title":"HLA-G and other immune checkpoint molecules as targets for novel combined immunotherapies","volume":"23","author":"Morandi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08830180215017","article-title":"Immunological relationship between the mother and the fetus","volume":"21","author":"Szekeres-Bartho","year":"2002","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31557\/apjcb.2018.3.2.37-45","article-title":"HLA-G: Facts and fictions","volume":"3","author":"Shahraki","year":"2018","journal-title":"Asian Pac. J. Cancer Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/jpet.109.164210","article-title":"Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule","volume":"333","author":"Ahmed","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2026.119230_bib34","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.4049\/jimmunol.171.11.5956","article-title":"Molecular cloning and immunologic characterization of a novel cDNA coding for progesterone-induced blocking factor","volume":"171","author":"Polgar","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119230_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108858","article-title":"Progesterone-induced blocking factor-mediated Th1\/Th2 balance correlates with fetal arrest in women who underwent in vitro fertilization and embryo transfer","volume":"232","author":"Lan","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biopha.2026.119230_bib36","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3389\/fimmu.2018.02890","article-title":"The role of extracellular vesicles and PIBF in embryo-maternal immune-interactions","volume":"9","author":"Szekeres-Bartho","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119230_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fimmu.2020.00349","article-title":"Altered immune response and implantation failure in progesterone-induced blocking factor-deficient mice","volume":"11","author":"Csabai","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijc.20326","article-title":"PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome","volume":"112","author":"Lachmann","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2026.119230_bib39","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1007\/s00018-013-1404-3","article-title":"Progesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity","volume":"70","author":"Halasz","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119230_bib40","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.21873\/anticanres.13479","article-title":"Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and\/or increased longevity for patients with a variety of different advanced cancers\u2013a review","volume":"39","author":"Check","year":"2019","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10571-014-0031-3","article-title":"Cells isolated from human glioblastoma multiforme express progesterone-induced blocking factor (PIBF)","volume":"34","author":"Kyurkchiev","year":"2014","journal-title":"Cell. Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119230_bib42","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1080\/10428190701471999","article-title":"Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone","volume":"48","author":"Srivastava","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.biopha.2026.119230_bib43","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.4049\/jimmunol.171.11.5956","article-title":"Molecular cloning and immunologic characterization of a novel cDNA coding for progesterone-induced blocking factor","volume":"171","author":"Polgar","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib44","article-title":"Proliferative and invasive effects of progesterone-induced blocking factor in human glioblastoma cells","volume":"2017","author":"Guti\u00e9rrez-Rodr\u00edguez","year":"2017","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2603095","article-title":"Assessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol","volume":"27","author":"Arcos-Montoya","year":"2026","journal-title":"Cancer Biol. Ther."},{"issue":"13_Supplement","key":"10.1016\/j.biopha.2026.119230_bib46","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-605","volume":"81","author":"Check","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/cancers13030512","article-title":"PGRMC proteins are coming of age: a special issue on the role of PGRMC1 and PGRMC2 in metabolism and cancer biology","volume":"13","author":"Cahill","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119230_bib48","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fbioe.2019.00438","article-title":"Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities","volume":"7","author":"Zhao","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12860-020-00256-3","article-title":"PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth","volume":"21","author":"Thejer","year":"2020","journal-title":"BMC Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13058-020-01312-8","article-title":"Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression","volume":"22","author":"Asperger","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119230_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.787848","article-title":"Maternal fatty acid metabolism in pregnancy and its consequences in the feto-placental development","volume":"12","author":"Duttaroy","year":"2022","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib52","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1038\/ncomms11030","article-title":"Haem-dependent dimerization of PGRMC1\/Sigma-2 receptor facilitates cancer proliferation and chemoresistance","volume":"7","author":"Kabe","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/jox14020034","article-title":"Pleiotropy of progesterone receptor membrane component 1 in modulation of cytochrome P450 activity","volume":"14","author":"Barata","year":"2024","journal-title":"J. Xenobiotics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2026.119230_bib55","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119230_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: an immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib57","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massagu\u00e9","year":"2008","journal-title":"Cell"},{"issue":"6348","key":"10.1016\/j.biopha.2026.119230_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"issue":"10-13","key":"10.1016\/j.biopha.2026.119230_bib60","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.steroids.2003.08.007","article-title":"Progesterone antagonists and progesterone receptor modulators: an overview","volume":"68","author":"Spitz","year":"2003","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/humupd\/dmi002","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"11","author":"Chabbert-Buffet","year":"2005","journal-title":"Hum. Reprod. Update"},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib62","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2026.119230_bib63","first-page":"2977","article-title":"Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia","volume":"29","author":"Check","year":"2009","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib64","first-page":"119","article-title":"Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer","volume":"30","author":"Check","year":"2010","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib65","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.21873\/anticanres.13301","article-title":"Mifepristone extends both length and quality of life in a patient with advanced non-small cell lung cancer that has progressed despite chemotherapy and a check-point inhibitor","volume":"39","author":"Check","year":"2019","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119230_bib66","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.21873\/anticanres.11251","article-title":"Long-term high-quality survival with single-agent mifepristone treatment despite advanced cancer","volume":"36","author":"Check","year":"2016","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119230_bib67","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.21873\/anticanres.17911","article-title":"Good quality 66.7% 5-year overall survival in terminal lung cancer patients treated with mifepristone","volume":"45","author":"Check","year":"2025","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib68","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","article-title":"Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)","volume":"156","author":"Touat","year":"2014","journal-title":"Acta Neurochir."},{"issue":"5","key":"10.1016\/j.biopha.2026.119230_bib69","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1078-0432.CCR-22-2060","article-title":"Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: results from the MIPRA trial","volume":"29","author":"El\u00eda","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00404-023-06996-9","article-title":"Impact of progesterone on the immune system in women: a systematic literature review","volume":"309","author":"Zwahlen","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.biopha.2026.119230_bib71","doi-asserted-by":"crossref","first-page":"406","DOI":"10.37349\/ei.2021.00027","article-title":"Progesterone induced blocking factor in health and disease","volume":"1","author":"Szekeres-Bartho","year":"2021","journal-title":"Explor. Immunol."},{"key":"10.1016\/j.biopha.2026.119230_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818783911","article-title":"High immune expression of progesterone-induced blocking factor in epithelial ovarian cancer","volume":"17","author":"Madendag","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.biopha.2026.119230_bib73","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa012","article-title":"Selective progesterone receptor modulators\u2014mechanisms and therapeutic utility","volume":"41","author":"Islam","year":"2020","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2026.119230_bib74","article-title":"Progesterone receptor modulators for endometriosis","author":"Fu","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib75","first-page":"315","article-title":"Mechanism of action of ulipristal acetate for emergency contraception: a systematic review","author":"Rosato","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib76","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","article-title":"Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer","volume":"35","author":"Robertson","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1749-6632.2002.tb02798.x","article-title":"Selective progesterone receptor modulators (SPRMs) a novel therapeutic concept in endometriosis","volume":"955","author":"Chwalisz","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib78","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","article-title":"Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance","volume":"13","author":"Morris","year":"2011","journal-title":"AAPS J."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119230_bib79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0303-7207(01)00743-2","article-title":"CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914","volume":"188","author":"Attardi","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"issue":"21","key":"10.1016\/j.biopha.2026.119230_bib80","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/cmdc.201800487","article-title":"Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies","volume":"13","author":"M\u00f6ller","year":"2018","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib81","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/annonc\/mdt216","article-title":"Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer","volume":"24","author":"Jonat","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119230_bib82","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3390\/cancers15072128","article-title":"Baicalein as promising anticancer agent: a comprehensive analysis on molecular mechanisms and therapeutic perspectives","volume":"15","author":"Morshed","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12672-020-00382-6","article-title":"Baicalein is a phytohormone that signals through the progesterone and glucocorticoid receptors","volume":"11","author":"Austin","year":"2020","journal-title":"Horm. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acs.jnatprod.1c01008","article-title":"The flavonoid baicalein negatively regulates progesterone target genes in the uterus in vivo","volume":"85","author":"Li","year":"2021","journal-title":"J. Nat. Prod."},{"issue":"8","key":"10.1016\/j.biopha.2026.119230_bib85","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12272-022-01397-z","article-title":"Latest research progress on anticancer effect of baicalin and its aglycone baicalein","volume":"45","author":"Wang","year":"2022","journal-title":"Arch. Pharmacol. Res."},{"issue":"15","key":"10.1016\/j.biopha.2026.119230_bib86","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1016\/j.bmc.2018.07.037","article-title":"Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model","volume":"26","author":"Jiang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119230_bib87","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3390\/nu15061407","article-title":"Kaempferol, a phytoprogestin, induces a subset of progesterone-regulated genes in the uterus","volume":"15","author":"Bergsten","year":"2023","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.biopha.2026.119230_bib88","first-page":"136","article-title":"Kaempferol exhibits progestogenic effects in ovariectomized rats","volume":"5","author":"Toh","year":"2014","journal-title":"J. Steroids Horm. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12672-018-0333-x","article-title":"The flavonoid apigenin is a progesterone receptor modulator with in vivo activity in the uterus","volume":"9","author":"Dean","year":"2018","journal-title":"Horm. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119230_bib90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12672-012-0114-x","article-title":"Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors","volume":"3","author":"Mafuvadze","year":"2012","journal-title":"Horm. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119230_bib91","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.steroids.2012.03.013","article-title":"Biological characterization of non-steroidal progestins from botanicals used for women\u2019s health","volume":"77","author":"Toh","year":"2012","journal-title":"Steroids"},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib92","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3390\/biomedicines12102405","article-title":"Apigenin as a promising agent for enhancing female reproductive function and treating associated disorders","volume":"12","author":"Sirotkin","year":"2024","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.biopha.2026.119230_bib93","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1940-6207.CAPR-10-0382","article-title":"Apigenin prevents development of medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in Sprague\u2013Dawley rats","volume":"4","author":"Mafuvadze","year":"2011","journal-title":"Cancer Prev. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119230_bib94","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s42255-019-0032-0","article-title":"Metabolic signatures of cancer cells and stem cells","volume":"1","author":"Intlekofer","year":"2019","journal-title":"Nat. Metab."},{"issue":"9","key":"10.1016\/j.biopha.2026.119230_bib95","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1074\/jbc.M008496200","article-title":"A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-\u03b2","volume":"276","author":"Lefebvre","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119230_bib96","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.1996.14.10.2709","article-title":"Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study","volume":"14","author":"Perrault","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"5930","key":"10.1016\/j.biopha.2026.119230_bib97","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"6155","key":"10.1016\/j.biopha.2026.119230_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119230_bib99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:46:39Z","timestamp":1779245199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":99,"alternative-id":["S0753332226002635"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119230","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The trophoblastic theory of cancer: Progesterone-dependent immune tolerance and modulation by synthetic and natural antagonists","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119230"}}